by Paul Crozier | Oct 29, | HiTech Health Latest News
Advanced therapies, including cell and gene therapies, are transforming the treatment landscape, offering new possibilities for patients with serious and life-threatening diseases. However, delivering these therapies requires more than advanced science and manufacturing. Successful patient treatment demands a carefully coordinated supply chain that integrates logistics, quality assurance, regulatory compliance and clinical operations.
Unlike conventional medicines, many advanced therapies have specific handling requirements, limited shelf lives or patient-specific manufacturing processes. These characteristics mean that traditional pharmaceutical supply-chain models may not always be appropriate.
The supply chain must therefore be designed around the patient and the treatment pathway from the outset, rather than treated as a downstream logistics consideration.
The Patient is at the Centre of the Supply Chain
It is essential that the patient remains the central priority when designing and establishing a supply chain for an advanced therapy. For example, with autologous cell therapies, the process often begins with collecting cells from the patient, transporting them to a manufacturing facility and returning the finished therapy to the treatment centre for administration to that same patient.
This involves multiple stakeholders, including collection centres, logistics providers, manufacturers, testing laboratories, Qualified Persons (QPs) responsible for batch certification, and clinical sites.
Each stakeholder has a critical role, and delays at any stage can affect the treatment schedule. Collection appointments, manufacturing capacity, transport arrangements, testing, product release and clinical site availability must therefore be coordinated well in advance. An experienced and responsive team is essential to achieving effective coordination.
Protecting Product Quality Throughout the Journey
Many advanced therapies are sensitive to temperature, humidity, transit duration and handling conditions. Depending on the product, maintaining product quality may require stringent ultra-low-temperature storage and monitoring, including the use of liquid nitrogen.
These requirements must be considered and incorporated into the supply-chain strategy, supported by appropriate procedures, qualified equipment and documented controls.
Key considerations include:
- Temperature control: Maintaining appropriate storage and transport conditions, with suitable monitoring and temperature excursion management.
- Transport qualification: Ensuring that shipping systems and distribution arrangements are suitable for the product.
- Contingency planning: Establishing responses to delays, equipment failures and temperature excursions.
- Receiving arrangements: Confirming that the destination facility can receive and store the product under the required conditions.
The appropriate controls will depend on the specific requirements of the advanced therapy. A risk-based approach is essential to maintaining product quality throughout the supply chain.
Maintaining Chain of Identity and Chain of Custody
For patient-specific therapies, ensuring that the right product reaches the right patient is fundamental.
Chain of identity (COI) maintains the link between the patient, their collected starting material and the resulting medicinal product. Chain of custody (COC) documents the possession and handling of materials and products throughout their journey.
These controls must extend across collection centres, couriers, manufacturers, testing laboratories and treatment facilities. Consistent identification, verification procedures and documentation at every handover help minimise the risk of errors.
Where multiple organisations and electronic systems are involved, differences in identifiers and processes can introduce additional complexity. These interfaces should be addressed during supply-chain design, with patient confidentiality also considered in labelling and information-sharing arrangements. Traceability is not simply a documentation exercise but it is a fundamental patient-safety control.
Integrating Qualified Person (QP) Certification into the Treatment Timeline
Quality control testing, thorough review of manufacturing documentation (including batch records) and Qualified Person (QP) certification are essential steps in ensuring regulatory compliance and product quality in the EU and UK.
For advanced therapies, these activities may need to be coordinated within a defined treatment window. The applicable requirements will depend on the product, regulatory framework and relevant clinical trial or marketing authorisation arrangements.
Early planning should establish the responsibilities of the manufacturer and QP, applicable importation requirements, documentation flows and procedures for escalating quality issues. Delays in testing or documentation can affect not only product release but also transport arrangements, receipt of shipments at clinical sites and patient treatment schedules.
QP certification should therefore be embedded within the overall supply-chain strategy from the outset, rather than treated as a standalone final step. For advanced therapies, early engagement with an experienced QP service provider is particularly important to ensure that regulatory requirements are addressed proactively and the supply chain is designed to meet the specific needs of both the product and the patient.
Building Resilience Through Early Planning
Even well-designed supply chains can encounter unexpected challenges, including flight delays, extended customs holds, manufacturing process changes or issues at receiving sites. For therapies with limited stability or patient-specific manufacturing windows, these disruptions can have significant consequences.
Sponsors should establish clear escalation procedures, identify alternative transport arrangements where appropriate, confirm suitable storage options and ensure that regulatory documentation is prepared before shipment. Responsibilities for managing delays, deviations and other disruptions should also be agreed in advance.
As clinical trials expand into additional countries, the supply chain may need to evolve. A supply-chain model that is suitable for a small, early-phase study may not be fit for purpose as the programme scales to a larger, multi-centre clinical trial.
By addressing these considerations early, clearly defining responsibilities and establishing robust processes across participating organisations, sponsors can build more resilient and predictable supply chains.
At HiTech Health, we recognise the importance of integrating quality, regulatory and supply-chain considerations to support the delivery of advanced therapies. Early collaboration can help sponsors navigate operational complexity while keeping the focus on delivering the right therapy to the right patient.
If you are developing an advanced therapy and planning clinical supply in the EU or UK, engaging an experienced QP and Quality team early can help identify potential challenges before they affect your programme. Contact our team today and schedule a call to learn more about our services for the EU and UK markets.
by Paul Crozier | Aug 27, | HiTech Health Latest News
Bringing a new therapeutic product from a process development laboratory into GMP manufacturing is a major milestone. While research processes are designed to demonstrate proof of concept, GMP manufacturing requires a process that is robust, reproducible and capable of consistently producing product that meets quality standards.
Moving into GMP before you are ready can result in delays, deviations and unnecessary costs. Before taking this step, sponsors should consider whether their process is truly ready.
Is Your Process Well Understood?
Successful laboratory experiments are only the beginning. Before GMP manufacture, you should understand the critical process parameters, expected product quality and sources of variability. A process that consistently delivers the same outcome is far more likely to transfer successfully into a GMP facility.
Are Your Materials and Formulation Ready?
Research-grade materials may not be suitable for clinical manufacturing. Key raw materials should be appropriately qualified and available from reliable suppliers. In addition, the formulation should be appropriately developed to avoid significant changes once GMP manufacturing has commenced.
Can the Process Be Manufactured Aseptically?
Sterile manufacturing requires careful consideration of contamination risks. Processes should minimise open handling, unnecessary interventions and other activities that could compromise sterility. Designing with aseptic manufacture in mind from an early stage can simplify the transition into GMP production.
Is the Required Documentation in Place?
Clear documentation is fundamental to GMP compliance. Manufacturing work instructions, material specifications, risk assessments and Standard Operating Procedures (SOPs) should all be development and implemented well before manufacturing begins. Effective documentation helps ensure consistency and reduces the risk of errors during manufacturing.
Have You Planned for Technology Transfer?
Technology transfer involves much more than sharing a manufacturing protocol. It requires effective communication between the development team and the manufacturing site, allowing practical challenges to be identified and addressed before GMP production starts. Engineering batches and collaborative planning can significantly improve the likelihood of a successful transfer.
The transition from laboratory development to sterile GMP manufacturing is a critical step that requires confidence that your process can consistently deliver high-quality product within a controlled manufacturing environment. Taking the time to evaluate process readiness can reduce risks, avoid costly delays and provide a stronger foundation for clinical supply. Engaging with an experienced manufacturing partner early can also help identify potential gaps before they become potential issues during GMP production.
We offer sterile manufacturing and aseptic fill-finish services within our GMP-certified cleanrooms. Our experienced team is committed to delivering the highest standards of compliance, quality, and reliability. If you’re seeking a trusted CDMO partner capable of providing exceptional results and ensuring continuity of supply, we’d be delighted to speak with you. Contact our team today and schedule a call to learn more.
by Paul Crozier | Aug 13, | HiTech Health Latest News
The UK has long been recognised as one of the world’s leading destinations for clinical research. Home to world-class universities, an integrated healthcare system and a thriving life sciences sector, it offers an environment that enables innovative therapies including new cell and gene therapies to move efficiently from the laboratory to the clinic.
For biotechnology companies seeking to expand their clinical development programmes, the UK provides a complete clinical trial ecosystem and numerous advantages including:
A World-Leading Research Environment
The UK consistently ranks among the global leaders in life sciences research. Universities such as Oxford, Cambridge, Imperial College London and University College London have helped establish a strong pipeline of scientific innovation, supported by internationally recognised research hospitals and academic clinical centres.
This close collaboration between academia, healthcare providers and industry enables new therapies to progress efficiently into clinical evaluation.
Access to the NHS
One of the UK’s greatest strengths is the National Health Service (NHS), which provides access to a single, integrated healthcare system covering a large and diverse patient population.
For clinical trial sponsors, this can support efficient patient identification and recruitment while providing investigators with access to comprehensive clinical expertise across a broad range of therapeutic areas.
A Supportive Regulatory Environment
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) continues to promote innovation while maintaining high standards of patient safety.
Recent regulatory reforms have focused on improving the efficiency of clinical trial approvals, helping to make the UK an increasingly attractive destination for both early- and late-phase clinical studies.
A Strong Advanced Therapy Ecosystem
The UK has established itself as a global leader in advanced therapies, including cell and gene therapies. Specialist treatment centres and a highly experienced workforce have created an environment that supports the development of these complex products from early research through to commercialisation.
This expertise has attracted both emerging biotechnology companies and multinational pharmaceutical organisations looking to conduct advanced therapy clinical trials.
An Established Clinical Trial Infrastructure
Successful clinical trials depend on more than investigators and patients. The UK benefits from an extensive network of experienced Contract Research Organisations (CROs), Qualified Person (QP) service providers like HiTech Health, logistics providers and experienced consultants that support every stage of clinical development.
This mature infrastructure enables sponsors to access the expertise required to manage manufacturing, regulatory compliance, importation of Investigational Medicinal Products (IMPs), QP certification and clinical supply.
Looking Ahead
As clinical development becomes increasingly global, the UK continues to offer an attractive combination of scientific excellence, regulatory expertise and operational capability.
For biotechnology companies planning future clinical programmes, the UK’s collaborative life sciences ecosystem provides access to the knowledge, infrastructure and specialist partners needed to support efficient and successful clinical trials.
Whether conducting a first-in-human study or expanding an international development programme, the UK remains one of the world’s most compelling locations for clinical research.
Let’s Talk!
Successfully conducting a clinical trial in the UK requires careful planning, robust quality systems, and compliance with regulatory requirements. Qualified Person services play a critical role in ensuring investigational medicinal products are manufactured, assessed, and released in accordance with GMP and clinical trial regulations.
Whether supporting IMP certification, importation activities, or ongoing quality oversight, an experienced QP provider like HiTech Health can help sponsors navigate the complexities of clinical trial compliance and keep development programmes moving forward.
Contact our team today and schedule a call to learn more about our services for the EU and UK markets.
by Paul Crozier | Jul 21, | HiTech Health Latest News
For companies manufacturing or importing medicinal products into the EU or UK, the role of the Qualified Person (QP) is a mandatory regulatory requirement. What exactly is a QP, and why is this role so important?
What is the Role of a Qualified Person?
A Qualified Person (QP) is a highly trained and experienced professional who is legally responsible for ensuring that medicinal products meet all required quality, safety, and regulatory standards before they are released to the market or for use in clinical trials.
The QP must certify that each batch of a medicinal product has been manufactured and tested in accordance with Good Manufacturing Practice (GMP), the product’s Marketing Authorisation/Clinical Trial Authorisation, and all applicable regulations.
Why is a QP Required?
The QP requirement was established to protect patients and maintain confidence in the supply chain of medicinal products. Before any medicinal product can be distributed in the EU or UK, a QP must formally certify that the batch complies with regulatory requirements.
This independent oversight helps to:
- Ensure patient safety
- Verify compliance with GMP regulations
- Confirm product quality and consistency
- Support regulatory inspections and audits
- Reduce the risk of defective or non-compliant products reaching the market
When is QP Certification Needed?
QP certification is required for:
- Commercial (‘to-market’) batch release of medicinal products:
- Manufactured within the EU or UK
- Imported from countries outside the EU or UK
- Investigational Medicinal Products (IMPs) used in clinical trials
Without QP certification, medicinal products cannot legally be released for sale or supply within the relevant market or for use in clinical trials.
Can I Outsource the QP requirement?
Many pharmaceutical and biotechnology companies choose to outsource QP responsibilities to experienced consultants or specialist service providers like HiTech Health. External organisations can support organisations with batch certification, GMP compliance, quality oversight, regulatory inspections, and supply chain management. However, it is important to do a thorough due diligence and select an experienced and trusted provider.
By partnering with an experienced company like HiTech Health, companies can ensure compliance with complex regulatory requirements while maintaining efficient product release timelines. The Qualified Person plays a vital role in safeguarding the quality and safety of medicinal products across the EU and UK. Whether for routine batch release, product importation, or clinical trial supply, QP certification is a legal requirement that helps ensure patients receive medicines that meet the highest standards of quality and compliance. We can help with all quality and compliance activities from your overall quality management system through quality audits and QMS remediation support.
Contact our team today and schedule a call to learn more about our QP services for the EU and UK markets.
by Paul Crozier | Jun 29, | HiTech Health Latest News
Successfully conducting a clinical trial in the UK extends beyond developing an Investigational Medicinal Product (IMP) and recruiting participants. Sponsors must also establish robust regulatory, quality, and operational processes to safeguard participant safety, ensure the integrity of clinical data, and comply with Medicines and Healthcare products Regulatory Agency (MHRA) requirements. Understanding these requirements early can help avoid costly delays and support a successful clinical development programme.
Regulatory Approval
Before a clinical trial can begin, sponsors must obtain the necessary approvals from the relevant authorities. These typically include:
- Clinical Trial Authorisation (CTA) from the MHRA
- Approval from a Research Ethics Committee (REC)
- Site-specific approvals and contracts where required
The application process requires detailed information on the investigational medicinal product, study protocol, investigator brochure, and supporting quality documentation.
Investigational Medicinal Product (IMP) Manufacturing
Any investigational medicinal product used in a clinical trial must be manufactured in accordance with Good Manufacturing Practice (GMP). This includes:
- Manufacturing under an appropriate GMP licence
- Validated manufacturing and testing processes
- Quality control testing
- Stability studies
- Comprehensive batch documentation that will be reviewed by a Qualified Person (QP)
Maintaining GMP compliance throughout the manufacturing process is essential to ensure the quality, safety, and consistency of the IMP.
Qualified Person (QP) Certification
One of the most important requirements for clinical trials involving medicinal products is QP certification.
Before an IMP can be released for use in a UK clinical trial, a Qualified Person (QP) must certify that each batch has been manufactured and tested in accordance with GMP requirements, the clinical trial application, and applicable regulations.
QP certification provides an independent assessment of product quality and helps ensure that trial participants receive investigational products that meet the required standards.
IMP Importation and Supply Chain Management
Where investigational products are manufactured outside the UK, additional controls may be required to ensure compliance with UK regulations. Sponsors must consider:
- Importation requirements
- Supply chain oversight
- Temperature-controlled distribution
- Storage and accountability procedures
- Product traceability throughout the trial
A QP can play a key role in reviewing imported product documentation and supporting compliant batch release activities.
Ongoing Quality Oversight
Clinical trial compliance does not end once the study begins. Sponsors must maintain robust quality systems to manage:
- Deviations and non-conformances
- Product complaints
- Quality investigations
- Change controls
- Product recalls, if required
Experienced QPs can provide valuable support in assessing quality events, performing risk assessments, and ensuring regulatory expectations are met throughout the study lifecycle.
Why Engage a Qualified Person Early?
Many sponsors engage QP services at an early stage of development to avoid delays during clinical trial preparation and product release. Early QP involvement can help with:
- IMP release strategy
- GMP compliance assessments
- Batch certification
- Importation requirements
- Quality documentation review
- Investigation and recall support
- Regulatory inspection readiness
By incorporating QP expertise into the clinical trial programme from the outset, sponsors can reduce compliance risks and maintain confidence in their product supply chain.
Conclusion
Successfully conducting a clinical trial in the UK requires careful planning, robust quality systems, and compliance with regulatory requirements. Qualified Person services play a critical role in ensuring investigational medicinal products are manufactured, assessed, and released in accordance with GMP and clinical trial regulations.
Whether supporting IMP certification, importation activities, or ongoing quality oversight, an experienced QP provider like HiTech Health can help sponsors navigate the complexities of clinical trial compliance and keep development programmes moving forward.
Contact our team today and schedule a call to learn more about our services for the EU and UK markets.
